

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2020

**Lantern Pharma Inc.**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or Other Jurisdiction of Incorporation)	<b>001-39318</b> (Commission File Number)	<b>46-3973463</b> (IRS Employer Identification No.)
--	---	---

<b>1920 McKinney Avenue, 7th Floor Dallas, Texas</b> (Address of Principal Executive Offices)	<b>75201</b> (Zip Code)
--	----------------------------

**(972) 277-1136**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.0001 par value	LTRN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

### Item 3.02 Unregistered Sales of Equity Securities.

Effective June 15, 2020, all of our outstanding shares of Series A Preferred Stock were converted into 2,438,851 shares of common stock in the aggregate after giving effect to a 1.74 for 1 forward stock split that occurred in connection with our initial public offering (“IPO”). The conversion of the Series A preferred stock into shares of common stock was exempt from registration pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”).

Effective June 15, 2020, we granted to ten award recipients consisting of directors, officers, or employees options to purchase a total of 306,743 shares of common stock in the aggregate at an exercise price equal to \$15.00 per share under our Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended. The foregoing issuance did not involve any underwriters and it was not deemed to be a public offering. We believe the offer, sale and issuance of the above options were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act because the issuance of securities to the recipients did not involve a public offering. The sales of those securities were made without any general solicitation or advertising.

### Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

In connection with our IPO, we filed an Amendment to our Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1.74 for 1 forward stock split which became effective on June 11, 2020.

In addition, in connection with our IPO, we filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which became effective on June 15, 2020, to (i) increase the number of authorized shares of capital stock to 26,000,000 of which 25,000,000 shares shall be common stock and 1,000,000 shares shall be preferred stock; and (ii) eliminate the designation of Series A preferred stock.

Our board of directors and stockholders previously approved the Amendment and the Restated Certificate in connection with our IPO.

The foregoing description of the Amendment and the Restated Certificate is qualified in its entirety by reference to the full text of the Amendment and the Restated Certificate, copies of which are attached hereto as Exhibits 3.1(iv) and (v) and are incorporated herein by reference.

### Item 8.01 Other Information.

On June 15, 2020, we issued a press release announcing the closing of our initial public offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information disclosed under this Item 8.01, including Exhibit 99.1, is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Exchange Act, except as expressly set forth by specific reference in such filing.

### Item 9.01 Financial Statement and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Exhibit Description</u>
3.1(iv)	<a href="#">Amendment to Certificate of Incorporation</a>
3.1(v)	<a href="#">Amended and Restated Certificate of Incorporation</a>
99.1	<a href="#">Press release announcing the closing of the initial public offering.</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lantern Pharma Inc.,  
A Delaware Corporation

Dated: June 16, 2020

By: /s/ David R. Margrave  
David R. Margrave, Secretary

# Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "LANTERN PHARMA INC.", FILED IN THIS OFFICE ON THE TENTH DAY OF JUNE, A.D. 2020, AT 5:59 O`CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT IS THE ELEVENTH DAY OF JUNE, A.D. 2020 AT 12:01 O`CLOCK A.M.



A handwritten signature in black ink, appearing to read "JBULLOCK", is written over a horizontal line. Below the line, the text "Jeffrey W. Bullock, Secretary of State" is printed in a small font.

7801204 8100  
SR# 20205624986

Authentication: 203085993  
Date: 06-10-20

You may verify this certificate online at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

---

**CERTIFICATE OF AMENDMENT  
TO  
CERTIFICATE OF INCORPORATION  
OF  
LANTERN PHARMA INC.**

State of Delaware  
Secretary of State  
Division of Corporations  
Delivered 05:59 PM 06/10/2020  
FILED 05:59 PM 06/10/2020  
SR 20205624986 - File Number 7801204

Lantern Pharma Inc., a corporation organized and existing under the laws of the State of Delaware (hereinafter called the "Corporation"), does hereby certify as follows:

FIRST: That this Certificate of Amendment to Certificate of Incorporation ("Certificate of Amendment") amends certain provisions of the Certificate of Incorporation of the Corporation ("Certificate of Incorporation") filed with the Secretary of State of the State of Delaware on January 15, 2020.

SECOND: The Board of Directors (the "Board") duly adopted resolutions approving the following amendment to the Certificate of Incorporation in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware, wherein the Board declared the amendment to be advisable and recommended that the stockholders of the Corporation likewise adopt and approve the amendment.

THIRD: Section 4.2 of Article IV of the Certificate of Incorporation is hereby amended by adding the following new paragraph immediately following the first paragraph:

At the filing and Effective Time, pursuant to the Delaware General Corporation Law, of this Certificate of Amendment of the Corporation, each one share of Common Stock issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be split and subdivided into 1.74 shares of fully paid and nonassessable shares of Common Stock (the "Forward Split"). No fractional shares shall be issued in connection with the Forward Split. In lieu of any fractional shares of Common Stock to which the holder would otherwise be entitled upon the Forward Split, the Corporation shall pay cash equal to such fraction multiplied by the then fair market value of the Common Stock as determined by the Board. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (each individually an "Old Certificate", and collectively "Old Certificates"), shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been split. The Forward Split of the outstanding shares of Common Stock shall not affect the total number of shares of Common Stock that the Corporation is authorized to issue, which shall remain as set forth in Section 4.1.


FOURTH: That this Certificate of Amendment was duly adopted in accordance with Sections 242 and 228 of the General Corporation Law of the State of Delaware and amends the provisions of the Corporation's Certificate of Incorporation.

FIFTH: All other provisions of the Certificate of Incorporation shall remain in full force and effect.

SIXTH: This Certificate of Amendment shall become effective at 12:01 a.m., Eastern Daylight Time, on June 11, 2020 (the "Effective Time").

*[Balance of Page Intentionally Left Blank-Signature Page Follows]*

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to Certificate of Incorporation to be duly executed in its name on its behalf by its duly authorized officer as of the 10th of June, 2020.

Lantern Pharma Inc.  
  
By \_\_\_\_\_  
Panna Sharma, Chief Executive Officer and  
President

# Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF "LANTERN PHARMA INC.", FILED IN THIS OFFICE ON THE TWELFTH DAY OF JUNE, A.D. 2020, AT 2:29 O`CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID RESTATED CERTIFICATE IS THE FIFTEENTH DAY OF JUNE, A.D. 2020 AT 6 O`CLOCK A.M.



A handwritten signature in black ink, appearing to read "JWB", is written over a horizontal line. Below the line, the text "Jeffrey W. Bullock, Secretary of State" is printed.

7801204 8100  
SR# 20205669327

Authentication: 203099876  
Date: 06-12-20

You may verify this certificate online at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

**AMENDED AND RESTATED  
CERTIFICATE OF INCORPORATION  
OF  
LANTERN PHARMA INC.**

(Pursuant to Sections 242 and 245 of the  
General Corporation Law of the State of Delaware)

Lantern Pharma Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:

FIRST: The present name of the corporation is Lantern Pharma Inc. and the date of filing the original Certificate of Incorporation of the corporation with the Secretary of State of the State of Delaware was January 15, 2020.

SECOND: The date of the filing of the Certificate of Amendment to Certificate of Incorporation of the corporation with the Secretary of State of the State of Delaware was June 10, 2020.

THIRD: This Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law of the State of Delaware.

FOURTH: This Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware and restates, integrates and further amends the provisions of the corporation's Certificate of Incorporation.

FIFTH: This Amended and Restated Certificate of Incorporation shall be effective at 6:00 a.m., Eastern Daylight Time, on June 15, 2020 (the "Effective Time").

SIXTH: The Certificate of Incorporation of the corporation, as amended and restated herein, will at the Effective Time of this Amended and Restated Certificate of Incorporation, read as follows:

**ARTICLE I  
NAME OF THE CORPORATION**

The name of the corporation is Lantern Pharma Inc. (the "**Corporation**").

**ARTICLE II  
REGISTERED AGENT**

The address of the registered office of the Corporation in the State of Delaware is: 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of the registered agent of the Corporation at such address is: The Corporation Trust Company.

**ARTICLE III  
BUSINESS PURPOSE**

The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the “DGCL”).

#### **ARTICLE IV CAPITAL STOCK**

**Section 4.1 Authorized Classes of Stock.** The total number of shares of stock of all classes of capital stock that the Corporation is authorized to issue is 26,000,000, of which 25,000,000 shares shall be shares of common stock having a par value of \$0.0001 per share (“**Common Stock**”) and 1,000,000 shares shall be shares of preferred stock having a par value of \$0.0001 per share (“**Preferred Stock**”).

**Section 4.2 Common Stock.** Except as otherwise required by law, as otherwise provided in this Amended and Restated Certificate of Incorporation, and as otherwise provided in the resolution or resolutions, if any, adopted by the board of directors of the Corporation (the “**Board of Directors**”) with respect to any series of the Preferred Stock, the holders of the Common Stock shall exclusively possess all voting power. Each holder of shares of Common Stock shall be entitled to one vote for each share held by such holder. Subject to the rights of holders of any series of outstanding Preferred Stock, holders of shares of Common Stock shall have equal rights of participation in the dividends and other distributions in cash, stock, or property of the Corporation when, as and if declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefor and shall have equal rights to receive the assets and funds of the Corporation available for distribution to stockholders in the event of any liquidation, dissolution, or winding up of the affairs of the Corporation, whether voluntary or involuntary.

**Section 4.3 Preferred Stock.** Except as otherwise required by law, the Board of Directors shall have the full authority permitted by law to divide the authorized and unissued shares of Preferred Stock into series, and to provide for the issuance of such shares (in an aggregate amount not exceeding the aggregate remaining number of shares of Preferred Stock authorized by this Amended and Restated Certificate of Incorporation), as determined from time to time by the Board of Directors and stated, before the issuance of any shares thereof, in the resolution or resolutions providing for the issuance thereof. The Board of Directors shall have the authority to fix and determine and to amend the number of shares of any series of Preferred Stock that is wholly unissued or to be established and to fix and determine and to amend the designation, preferences, voting powers and limitations, and the relative, participating, optional or other rights, of any series of shares of Preferred Stock that is wholly unissued or to be established, including, without limiting the generality of the foregoing, the voting rights relating to shares of such series of Preferred Stock, the rate of dividend to which holders of shares of such series of Preferred Stock may be entitled, the rights of holders of shares of such series of Preferred Stock in the event of liquidation, dissolution or winding up of the affairs of the Corporation, the rights of holders of shares of such series of Preferred Stock to convert or exchange shares of such series of Preferred Stock for shares of any other capital stock or for any other securities, property or assets of the Corporation, and whether or not the shares of such series of Preferred Stock shall be redeemable and, if so, the term and conditions of such redemption.

**ARTICLE V  
BOARD OF DIRECTORS**

**Section 5.1 General Powers.** The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.

**Section 5.2 Number.** Subject to any rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the number of directors of the Corporation which shall constitute the entire Board of Directors shall consist of not less than three (3) and not more than nine (9) directors as fixed from time to time solely by resolution of at least a majority of the total number of directors that the Corporation would have at the time of such resolution if there were no vacancies adopting an amendment to the bylaws of the Corporation (the "Bylaws") setting forth the number of directors therein.

**Section 5.3 Newly Created Directorships and Vacancies.** Except as otherwise required by law and subject to any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances any newly created directorships resulting from an increase in the authorized number of directors and any vacancies occurring in the Board of Directors, shall be filled solely by the affirmative votes of a majority of the remaining members of the Board of Directors, although less than a quorum, or by a sole remaining director. A director so elected shall be elected to hold office until the earlier of the expiration of the term of office of the director whom he or she has replaced, a successor is duly elected and qualified, or the earlier of such director's death, resignation, or removal.

**Section 5.4 Written Ballot.** Unless and except to the extent that the Bylaws shall so require, the election of directors of the Corporation need not be by written ballot.

**ARTICLE VI  
LIMITATION OF LIABILITY; INDEMNIFICATION**

**Section 6.1 Limitation of Liability.** To the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or to its stockholders for monetary damages for any breach of fiduciary duty as a director. No amendment to, modification of, or repeal of this Section 6.1 shall apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment.

**Section 6.2 Indemnification.** The Corporation may indemnify to the fullest extent permitted by law as it presently exists or may hereafter be amended any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative, or investigative, by reason of the fact that he or she, his or her testator, or intestate is or was a director, officer, or employee, or agent of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as a director, officer, employee or agent at the request of the Corporation or any predecessor to the Corporation. Any amendment, repeal, or modification of this Section 6.2 shall not adversely affect any right or protection hereunder of

any person in respect of any act or omission occurring prior to the time of such amendment, repeal or modification.

## **ARTICLE VII STOCKHOLDER ACTION**

**Section 7.1 Stockholder Consent Prohibition.** Subject to the rights of the holders of any series of Preferred Stock and provided that the Corporation has registered its Common Stock under Section 12 of the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), or is required to file reports with the Securities and Exchange Commission under Section 15(d) of the Exchange Act, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders of the Corporation and may not be effected by any written consent by such stockholders without a meeting. At any time that both (i) the Common Stock of the Corporation is not registered under Section 12 of the Exchange Act and (ii) the Corporation is not required to file reports with the Securities and Exchange Commission under Section 15(d) of the Exchange Act, then any action required by the DGCL or other applicable Delaware law to be taken at any annual or special meeting of stockholders, or any action which may be taken at any annual or special meeting of stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.

**Section 7.2 Special Meetings of Stockholders.** Except as otherwise required by law and subject to the rights of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation shall be called only by: (i) the Board of Directors or (ii) the Secretary of the Corporation, following receipt of one or more written demands to call a special meeting of the stockholders from stockholders of record who own, in the aggregate, at least twenty five percent (25%) of the voting power of the outstanding shares of the Corporation then entitled to vote on the matter or matters to be brought before the proposed special meeting that complies with the procedures for calling a special meeting of the stockholders as may be set forth in the Bylaws.

## **ARTICLE VIII BYLAWS**

**Section 8.1 Board of Directors.** In furtherance and not in limitation of the powers conferred by law, the Board of Directors is expressly authorized and empowered to adopt, amend, alter, or repeal the Bylaws without any action on the part of the stockholders.

**Section 8.2 Stockholders.** The stockholders shall also have the power to adopt, amend, alter, or repeal the Bylaws; provided that, in addition to any affirmative vote of the holders of any particular class or series of capital stock of the Corporation required by applicable law or this Amended and Restated Certificate of Incorporation, such adoption, amendment, alteration, or repeal shall be approved by the affirmative vote of the holders of at least fifty percent (50%) of

the voting power of the shares of the then outstanding voting stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class.

**ARTICLE IX  
AMENDMENTS**

The Corporation reserves the right to amend, alter, or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by the laws of the State of Delaware, and all rights conferred herein are granted subject to this reservation; provided however, that notwithstanding any other provision of this Amended and Restated Certificate of Incorporation or applicable law that might permit a lesser vote or no vote and in addition to any affirmative vote of the holders of any particular class or series of capital stock of the Corporation required by applicable law or this Amended and Restated Certificate of Incorporation, the affirmative vote of the holders of at least fifty percent (50%) of the voting power of the shares of the then outstanding voting stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter, repeal, or adopt any provisions inconsistent with this Article IX or inconsistent with Article VII or Article VIII of this Amended and Restated Certificate of Incorporation.

*[signature page follows]*

THE UNDERSIGNED, being duly authorized to file this Amended and Restated Certificate of Incorporation in accordance with the General Corporation Law of the State of Delaware, does hereby file this Amended and Restated Certificate of Incorporation, and declare and certify that the facts herein stated are true and correct, and accordingly has hereunto set his hand this 12th day of June, 2020.

By: 

Name: Panna Sharma

Title: President, Chief Executive Officer, and  
Authorized Signatory



**FOR IMMEDIATE RELEASE**

Monday, June 15, 2020

## **Lantern Pharma Announces Closing of Initial Public Offering**

**DALLAS, TX / June 15, 2020** / Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, today announced the closing of its initial public offering of 1,750,000 shares of its common stock at a public offering price of \$15.00 per share, for gross proceeds of \$26,250,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 262,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.

ThinkEquity, a division of Fordham Financial Management, Inc. acted as sole book-running manager for the offering. Colliers Securities LLC and Paulson Investment Company, LLC acted as co-managers for the offering.

Registration statements on Form S-1 (Files No. **333-237714** and **333-239112**) relating to the shares were filed with the Securities and Exchange Commission (“SEC”) and became effective on June 10, 2020, or automatically became effective, as applicable. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at [prospectus@think-equity.com](mailto:prospectus@think-equity.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Lantern Pharma Inc.**

Lantern Pharma Inc. (LTRN) is a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology therapies. Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR<sup>®</sup>, currently includes more than 275 million data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development.

### **Forward Looking Statements**

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Lantern Pharma Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Lantern Pharma Inc. undertakes no duty to update such information except as required under applicable law.

### **Contact:**

Kyle Evans  
Public relations  
e: [lantern@fischtankpr.com](mailto:lantern@fischtankpr.com)  
p: 646-699-1414